Consequently, targeting GLP-1Rs’ activation with GLP-1 analogues and increasing GLP-1 half-life in the bloodstream became an area of interest for the management of obesity and T2D. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.